Abstract
Adalat (generic nifedipine), a dihydropyridine derivative, was recently developed by Bayer AG, West Germany. The substance represents a new type of drug with a remarkable antianginal effect when administered orally or sublingually even in small doses. The antianginal efficacy of Adalat is well documented by numerous reports.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1975 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kodama, K., Ohgitani, N., Minamino, T. (1975). Clinical-Therapeutic and Hemodynamic Studies with Adalat, a New Coronary Active Substance. In: Lochner, W., Braasch, W., Kroneberg, G. (eds) 2nd International Adalat® Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-66241-6_33
Download citation
DOI: https://doi.org/10.1007/978-3-642-66241-6_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-07471-7
Online ISBN: 978-3-642-66241-6
eBook Packages: Springer Book Archive